Jens Eickhoff

Featured in: Favicon

jamanetwork.com Favicon

tandfonline.com Favicon

liebertpub.com Favicon

ajpe.org + 3 more

Articles

1478 Phase 1/2 trial of androgen deprivation, with or without pTVG-AR, and with or without nivolumab, in patients with newly diagnosed, high-risk prostate cancer | Journal for ImmunoTherapy of Cancer

Nov 1, 2024 | jitc.bmj.com | Christos E. Kyriakopoulos |Jens Eickhoff |Laura Johnson |Tommaso P Tonelli

AbstractBackground We have previously evaluated a DNA vaccine encoding the ligand-binding domain of the androgen receptor (AR, pTVG-AR) in patients with metastatic prostate cancer. In murine studies we have demonstrated that the anti-tumor efficacy of androgen deprivation (ADT) can be improved using pTVG-AR vaccination, and that anti-tumor efficacy of vaccination can be improved with concurrent PD-1 blockade.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →